Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
종목 코드 COEPW
회사Coeptis Therapeutics Holdings Inc
CEO
웹사이트https://coeptistx.com/
자주 묻는 질문
Coeptis Therapeutics Holdings Inc(COEPW)의 현재 가격은 얼마인가요?
Coeptis Therapeutics Holdings Inc(COEPW)의 현재 주가는 0.013입니다.
Coeptis Therapeutics Holdings Inc의 종목 기호(Symbol)는 무엇인가요?
Coeptis Therapeutics Holdings Inc의 종목 코드는 COEPW입니다.